Address: 98 Armstrong Avenue
La Lucia Ridge
Durban
4019,South Africa
Tel: +27 31 5808600
Web: http://www.aspenpharma.com/
South African-based JSE Limited listed Aspen is a supplier of branded and generic pharmaceuticals in approximately 100 countries across the globe and of consumer and nutritional products in selected territories.
Aspen is represented in South Africa, Australia, Hong Kong, Kenya, Tanzania, Uganda, Dubai, Germany, Ireland, Mauritius, Brazil, Mexico and Venezuela.
Aspen has 18 manufacturing facilities at 13 pharmaceutical manufacturing sites on five continents. Four of the sites are located in South Africa, four in Australia, and one in each of Kenya, Tanzania, Brazil, Mexico and Germany.
Aspen is the leading supplier of generic medicines to both the private and public sectors in South Africa.
Aspen has production capabilities for a wide variety of product types including tablets, capsules, steriles, injectables, oral contraceptives, nutritional products, lyophilised vials, cytotoxics, suppositories, vials, form-filled seals, liquids, semi-solids and specialist active pharmaceutical ingredients.
Daniel Vella Friggieri, Regional CEO for Europe and the Middle East at Aspen Pharmacare, discusses the company’s growth trajectory over the past 18 months, highlighting the decision to merge the…
Vanja Hoeben oversees the Benelux cluster for South Africa-headquartered specialty and branded pharma firm Aspen. He describes the reorganisation that his organisation has undergone in the past few years, some…
Newly promoted to manage Aspen’s Middle East and Europe region, Daniel Vella Friggieri outlines the rationale behind the company’s strategic reconfiguration, how the South-Africa headquartered firm is looking to expand…
Aspen’s regional CEO for the Middle East, North Africa & Turkey, Daniel Vella Friggieri, provides insights into how the South African company’s federated model and decentralized management system translates into…
Aspen’s European Head Thomas Kerscher explains how the sale of the company’s thrombosis portfolio to Mylan has led to an organisational transformation in Europe with a leaner approach and an…
Miriam Rodriguez, general manager of Aspen Pharmacare Iberia, highlights the steps she has taken to set up the affiliate and how her past experiences have helped her. Furthermore, she breaks…
Franck Hamalian, general manager of the French affiliate of Aspen, a specialty and branded multinational pharmaceutical company from South Africa, discusses the Group’s unique business model which revolves around strategic…
Wojciech Sulimierski, general manager of Aspen Poland and CEE, discusses the opening of the regional operations in 2014 and the importance of the CEE region as the company establishes itself…
Alexandre França, CEO of Aspen Pharma Brazil, describes the transformation of the Brazilian organization over the past year, which allowed Aspen Brazil to establish itself as the best performing affiliate…
Carlos Alberto Florez, newly appointed general manager of Aspen Colombia, already has a very clear view on Aspen’s strategic direction, discussing the expansion of the infant nutrition segment and the…
Carlos Abelleyra Cordero, CEO Spanish Latin America of Aspen Labs, describes the rapid development of Aspen’s operational capacity throughout the region, in line with the company’s ambition to ultimately establish…
The head of Aspen sterile operations and managing director of Aspen NDB, reveals how their facility in France acts as the main platform for the group´s sterile business, a market…
From humble beginnings to one of the largest companies in Mauritius; the CEO of Aspen Global Incorporated Mauritius explains the significance of the Mauritian holding for one of the fastest…
Aspen Labs wants Latin America to be the third pillar of success for the company, and is doing it in a different way. The CEO for Spanish Latin America discusses…
Aspen Malaysia’s country manager details the company’s success in the country with a specific business model based on acquiring and remarketing originators. Although Aspen is a renowned generic player, market dynamics…
Marcelina Itchon, President & CEO of Aspen Philippines, talks about what drives Aspen’s success, why the Philippines was the first choice from which to build an Asian division, and the…
Marcelina Itchon, President & CEO of Aspen Philippines, talks about what drives Aspen’s success, why the Philippines was the first choice from which to build an Asian division, and the…
Marcelina Itchon, President & CEO of Aspen Philippines, talks about what drives Aspen’s success, why the Philippines was the first choice from which to build an Asian division, and the…
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
The Aspen Group identified Latin America as a “large developing market where it can leverage its substantial intellectual property portfolio and manufacturing infrastructure”. What was the original strategy behind getting…
Building on the recent controversy over Tanzania’s handling of a suspected Marburg virus outbreak, Medicines for Africa’s Lenias Hwenda explores how African nations often face disproportionate consequences for outbreak transparency—penalties…
John M. Mwangi of Bayer Pharmaceuticals, writing in the December 2024 edition of DIA’s Global Forum magazine, examines why longstanding calls to implant more of the pharmaceutical manufacturing chain into…
The IFPMA’s Sarah Adam, writing in the July 2024 edition of DIA’s Global Forum magazine, looks back on an insightful discussion on the progress towards an African Medicines Agency at…
Several major scientific breakthroughs in HIV prevention and treatment in the past 40 years have successfully transformed HIV from a near-certain ‘death sentence’ to a manageable chronic disease where many…
In 2024, people living with HIV have more, and more varied, access to HIV prevention and treatment options than ever before. Thanks to global activism efforts forcing pharma to step…
A leading voice in the global fight against HIV, Professor Linda-Gail Bekker works across both scientific research and activism. As CEO and founder of the Desmond Tutu Health Foundation, Prof…
Medicines for Africa’s Lenias Hwenda reflects on Moderna’s recent decision not to go ahead with plans for a vaccine manufacturing facility in Kenya, and why local production remains crucial to…
Medicines for Africa’s Lenias Hwenda argues that the success of the much-talked-about African Medicines Agency hinges on a critical mass of African national regulators achieving WHO Level 3 maturity status.…
Writing in the February 2024 edition of the DIA Global Forum magazine, Verena Pfaffinger and Ilona Baraniak-Lang of PharmaLex examine how the drug shortages seen in the global south during…
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Dr Benji Pretorius, the founder of Erada Technology Alliance and a malaria survivor himself, shares his insights into why the development of a truly effective malaria vaccine will only succeed…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Nevena Miletic of Roche and the IFPMA’s Africa Regulatory Network and Ian Hudson from the Bill and Melinda Gates…
See our Cookie Privacy Policy Here
